In prostate cancer cells, however, evodiamine caused an elevation in the activities of caspase-3 and caspase-9, but not caspase-8, in PC3 and LNCaP cells; and of caspase-3, caspase-9, and caspase-8 in DU145 cells [39,40]. Here, CASP3 is linked to prostate carcinoma.